NantKwest and ImmunityBio to initiate a phase 2 study of immunotherapy for metastatic pancreatic cancer
Four metastatic pancreatic cancer patients have been treated with PD-L1 t-haNK and N-803 under single patient INDs, with two patients on treatment for an evaluable period. One patient reported